AIMイムノテック（AIM ImmunoTech）が米国FDAからIND認可を受け、局所進行膵臓がんの治療におけるAmpligen®の第2相試験へ
March 16, 2022 18:08 ET
|
AIM ImmunoTech Inc.
これまでに確認されたデータは、アンプリジェン（アンプリゲン）（Ampligen®）（リンタトリモッド（rintatolimod））が進行性膵臓がん患者の全身化学療法後の維持療法として有効である可能性を示している ...
AIM ImmunoTech获美国FDA的IND许可以推进Ampligen®治疗局部晚期胰腺癌的2期研究
March 16, 2022 18:08 ET
|
AIM ImmunoTech Inc.
迄今为止的数据表明Ampligen®(rintatolimod)可能成为晚期胰腺癌患者系统化疗后的一种潜在的有效维持疗法 在一项单中心指定患者用药研究项目中，与未接受Ampligen的对照组相比，在FOLFIRINOX之后配合使用Ampligen治疗与胰腺癌患者的生存率提高相关 晚期胰腺癌2期研究预计将于年底前启动 佛罗里达州奥卡拉, March 17, 2022 (GLOBE...
AIM ImmunoTech Receives IND Clearance from the U.S. FDA to Advance its Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer
March 16, 2022 07:05 ET
|
AIM ImmunoTech Inc.
Data seen to date indicates that Ampligen® (rintatolimod) could be a potential effective maintenance therapy after systemic chemotherapy in patients with advanced pancreatic cancer In a...
AIM ImmunoTech宣布《Cancers》特刊《胰腺癌联合和创新疗法》发布晚期胰腺癌早期获取计划（EAP）阳性数据
March 09, 2022 16:00 ET
|
AIM ImmunoTech Inc.
Ampligen® （rintatolimod）正在荷兰伊拉斯谟医疗中心（Erasmus Medical Center）医疗检查机构批准的早期获取计划（EAP）中作为治疗胰腺癌患者的单药疗法接受评估 与未接受Ampligen的对照组相比，在FOLFIRINOX之后配合使用Ampligen治疗与胰腺癌患者的生存率提高相关 针对局部晚期胰腺癌患者的2期研究预计将于2022年第二季度/第三季度开始 ...
AIM ImmunoTech Announces Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the AACR 2022 Annual Meeting
March 09, 2022 07:35 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., March 09, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
AIM ImmunoTech Announces Abstracts from Roswell Park Comprehensive Cancer Center Accepted for Presentation in a Late-Breaking Poster Session at the AACR 2022 Annual Meeting
March 09, 2022 07:05 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., March 09, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
AIM ImmunoTech Announces Publication of Positive Data from Late-Stage Pancreatic Cancer Early Access Program (EAP) in the Cancers Special Issue: Combination and Innovative Therapies for Pancreatic Cancer
March 08, 2022 13:59 ET
|
AIM ImmunoTech Inc.
Ampligen® (rintatolimod) is being evaluated as a monotherapy to treat pancreatic cancer patients in an Early Access Program (EAP) approved by the Inspectorate of Healthcare in the Netherlands at...
AIM ImmunoTech Announces Strategic Sale of New Brunswick, New Jersey Facility to Allocate Additional Resources to Advance Pipeline
March 07, 2022 08:05 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., March 07, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
AIM ImmunoTech Appoints Robert Dickey, IV as Chief Financial Officer
March 03, 2022 08:35 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., March 03, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
AIM ImmunoTech to Participate in a Solve M.E. Diagnostics and Treatments Webinar
January 26, 2022 08:05 ET
|
AIM ImmunoTech Inc.
AIM ImmunoTech management to participate in webinar Thursday, January 27th from 2:00 pm - 3:00 pm ET Company to discuss clinical plans for investigational drug Ampligen for the treatment of myalgic...